Caxton Associates (UK)’s ARK Genomic Revolution ETF ARKG Stock Holding History

Caxton Associates (UK)’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.13M	Buy	+20,837	New	+$937K	0.02%	314

Other funds holding ARKG

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

MML Investors Services Springfield, Massachusetts $32.8B AUM 18.62% 1-Year Est. Return

Florin Court Capital London, United Kingdom $97M AUM 40.08% 1-Year Est. Return

Caxton Associates (UK)'s ARKG Position: Q3 2026 in Review

Caxton Associates (UK) opened a new position in ARK Genomic Revolution ETF (ARKG) in Q3 2026: 20,837 shares worth $1.13M. The stake represents 0.02% of the portfolio and ranks #314 among its holdings.

260 funds tracked by Wall St. Rank hold ARKG as of Q3 2026.

Caxton Associates (UK) held 20,837 shares of ARK Genomic Revolution ETF worth $1.13M as of Q3 2026.
ARK Genomic Revolution ETF was a new Caxton Associates (UK) position in Q3 2026.
ARK Genomic Revolution ETF made up 0.02% of Caxton Associates (UK)'s portfolio in Q3 2026, its #314 holding.
260 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2026.

Based on Caxton Associates (UK)'s 13F filing for Q3 2026, filed 13 Nov 2026.